NASDAQ:YS YS Biopharma (YS) Stock Price, News & Analysis $0.48 +0.01 (+2.14%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.47▼$0.5150-Day Range$0.44▼$1.0252-Week Range$0.35▼$1.78Volume14,725 shsAverage Volume172,401 shsMarket Capitalization$44.44 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get YS Biopharma alerts: Email Address YS Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside999.5% Upside$5.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.22 out of 5 starsMedical Sector790th out of 936 stocksPharmaceutical Preparations Industry369th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingYS Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageYS Biopharma has received no research coverage in the past 90 days.Read more about YS Biopharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for YS. Previous Next 0.0 Dividend Strength Dividend YieldYS Biopharma does not currently pay a dividend.Dividend GrowthYS Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for YS. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for YS Biopharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for YS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, YS Biopharma insiders have not sold or bought any company stock.Percentage Held by Institutions52.64% of the stock of YS Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about YS Biopharma's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for YS Biopharma are expected to grow in the coming year, from ($0.45) to ($0.25) per share.Price to Book Value per Share RatioYS Biopharma has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About YS Biopharma Stock (NASDAQ:YS)YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.Read More YS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart YS Stock News HeadlinesJuly 20, 2024 | seekingalpha.comLSB LakeShore Biopharma Co., LtdJuly 19, 2024 | benzinga.comPieris Pharmaceuticals (NASDAQ:PIRS) Stock Quotes, Forecast and News SummaryJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 24, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Name Change to LakeShore BiopharmaMay 24, 2024 | prnewswire.comYS Biopharma Announces Name Change to LakeShore BiopharmaMay 22, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General MeetingMay 21, 2024 | prnewswire.comYS Biopharma Announces Results of Extraordinary General MeetingMay 7, 2024 | prnewswire.comYS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive OfficerJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 7, 2024 | finance.yahoo.comWith 80% ownership, YS Biopharma Co., Ltd. (NASDAQ:YS) insiders have a lot riding on the company's futureApril 29, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleApril 29, 2024 | prnewswire.comYS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleApril 22, 2024 | finance.yahoo.comYS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call TranscriptApril 19, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 19, 2024 | markets.businessinsider.comYS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024April 19, 2024 | prnewswire.comYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024April 18, 2024 | finanznachrichten.deYS Biopharma Co., Ltd.: YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus VaccineSee More Headlines Receive YS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for YS Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:YS CUSIPN/A CIK1946399 Webwww.ysbiopharm.com Phone852-2155-7212FaxN/AEmployees773Year FoundedN/APrice Target and Rating Average Stock Price Target$5.25 High Stock Price Target$5.25 Low Stock Price Target$5.25 Potential Upside/Downside+999.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.26 Current Ratio0.94 Quick Ratio0.73 Sales & Book Value Annual Sales$560.76 million Price / Sales0.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book0.42Miscellaneous Outstanding Shares93,058,000Free FloatN/AMarket Cap$44.44 million OptionableNot Optionable Beta0.51 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Gang Li (Age 42)Head of Marketing & Sales Dr. Yuan Liu Ph.D. (Age 37)Head of Vaccine Research Dr. Hui Shao C.F.A. (Age 56)M.B.A., Ph.D., President, CEO & Executive Director Dr. Zenaida Reynoso Mojares M.D. (Age 65)Chief Medical Officer Key CompetitorsCitius PharmaceuticalsNASDAQ:CTXRSkye BioscienceNASDAQ:SKYEInnate PharmaNASDAQ:IPHAKodiak SciencesNASDAQ:KODAdverum BiotechnologiesNASDAQ:ADVMView All Competitors YS Stock Analysis - Frequently Asked Questions How have YS shares performed this year? YS Biopharma's stock was trading at $0.5110 at the beginning of 2024. Since then, YS shares have decreased by 6.6% and is now trading at $0.4775. View the best growth stocks for 2024 here. How do I buy shares of YS Biopharma? Shares of YS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:YS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding YS Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share YS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
